Trevi Therapeutics (TRVI) is initiated with a "Buy" rating, driven by its lead asset Haduvio’s advancement toward phase 3 testing for chronic cough in IPF. Company's Haduvio demonstrated statistically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback